Suppr超能文献

相似文献

1
Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
Structure. 2008 Mar;16(3):460-7. doi: 10.1016/j.str.2007.12.016.
3
Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
J Biol Chem. 2010 Mar 5;285(10):7035-44. doi: 10.1074/jbc.M109.096032. Epub 2009 Dec 18.
5
The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15024-9. doi: 10.1073/pnas.0507591102. Epub 2005 Oct 3.
6
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Pharmacol Res. 2019 Jan;139:395-411. doi: 10.1016/j.phrs.2018.11.014. Epub 2018 Nov 27.
7
Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
PLoS One. 2013 Aug 1;8(8):e69427. doi: 10.1371/journal.pone.0069427. Print 2013.
8
Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging.
J Biol Chem. 2013 Oct 18;288(42):30773-30784. doi: 10.1074/jbc.M113.489534. Epub 2013 Sep 6.
9
Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface.
Nature. 2007 Nov 29;450(7170):741-4. doi: 10.1038/nature05998.
10

引用本文的文献

1
Vitamin D ameliorates prediabetic cardiac injure via modulation of the ErbB4/ferroptosis signaling axis.
Front Immunol. 2025 Jul 17;16:1626295. doi: 10.3389/fimmu.2025.1626295. eCollection 2025.
4
HER4 is a high-affinity dimerization partner for all EGFR/HER/ErbB family proteins.
Protein Sci. 2024 Oct;33(10):e5171. doi: 10.1002/pro.5171.
5
Enabling target-aware molecule generation to follow multi objectives with Pareto MCTS.
Commun Biol. 2024 Sep 2;7(1):1074. doi: 10.1038/s42003-024-06746-w.
6
Identification of kinase modulators as host-directed therapeutics against intracellular methicillin-resistant .
Front Cell Infect Microbiol. 2024 Mar 25;14:1367938. doi: 10.3389/fcimb.2024.1367938. eCollection 2024.
9
An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations.
Cancer Res Commun. 2022 Jan 7;2(1):10-27. doi: 10.1158/2767-9764.CRC-21-0021. eCollection 2022 Jan.
10
Structure and dynamics of the EGFR/HER2 heterodimer.
Cell Discov. 2023 Feb 13;9(1):18. doi: 10.1038/s41421-023-00523-5.

本文引用的文献

1
Processing of X-ray diffraction data collected in oscillation mode.
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
2
Inter-conversion of neuregulin2 full and partial agonists for ErbB4.
Biochem Biophys Res Commun. 2007 Dec 14;364(2):351-7. doi: 10.1016/j.bbrc.2007.10.004. Epub 2007 Oct 11.
3
Breast cancer: the upgraded role of HER-3 and HER-4.
Int J Biochem Cell Biol. 2007;39(5):851-6. doi: 10.1016/j.biocel.2006.11.017. Epub 2006 Dec 27.
4
Targeting the EGFR pathway for cancer therapy.
Curr Med Chem. 2006;13(29):3483-92. doi: 10.2174/092986706779026174.
5
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.
Cell. 2006 Jun 16;125(6):1137-49. doi: 10.1016/j.cell.2006.05.013.
6
Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.
Bioorg Med Chem Lett. 2006 Sep 1;16(17):4686-91. doi: 10.1016/j.bmcl.2006.05.090. Epub 2006 Jun 13.
7
A Src-like inactive conformation in the abl tyrosine kinase domain.
PLoS Biol. 2006 May;4(5):e144. doi: 10.1371/journal.pbio.0040144. Epub 2006 May 2.
8
The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15024-9. doi: 10.1073/pnas.0507591102. Epub 2005 Oct 3.
9
ERBB receptors and cancer: the complexity of targeted inhibitors.
Nat Rev Cancer. 2005 May;5(5):341-54. doi: 10.1038/nrc1609.
10
Coot: model-building tools for molecular graphics.
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32. doi: 10.1107/S0907444904019158. Epub 2004 Nov 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验